Security
GRI Bio, Inc. Common Stock · GRI
GRINASDAQCommon stockCurrentCIK 1824293Updated Oct 6, 2026
Name history
Vallon Pharmaceuticals, Inc. · through Apr 21, 2023
GRI price & chart
Loading TradingView…
NASDAQ:GRI on TradingView ↗About the company
GRI Bio is a clinical-stage biopharmaceutical company focused on developing innovative therapies for inflammatory, fibrotic and autoimmune diseases. The Company's lead program, GRI-0621, is an oral RARβ/γ-selective agonist being developed for the treatment of idiopathic pulmonary fibrosis (IPF), a progressive and life-threatening fibrotic lung disease with significant unmet need. GRI-0621 is designed to modulate pathways associated with inflammation, fibrosis and tissue repair and is being evaluated as a potential novel oral therapeutic for patients with IPF.
In the news
Recent filings
ARS filing
DEF 14A filing
Regulation FD Disclosure · Other Events
Items 7.01, 8.01, 9.01
10-Q filing
Other Events
Items 8.01, 9.01
Show 5 more recent filings
Results of Operations and Financial Condition · Other Events
Items 2.02, 8.01, 9.01
10-Q filing
Results of Operations and Financial Condition
Items 2.02, 9.01
EFFECT filing
10-K filing
Financials
FY 2025 · USDSource
Source
Source
Source
Source
balance sheet · annual statements
| Line item | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q2 2024 | Q1 2026 | Q1 2025 | Q1 2024 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||||||
| AssetsUSD | 4,782,000Source | 5,459,000Source | 11,380,000Source | 5,675,000Source | 7,031,000Source | 11,339,000Source | 4,042,000Source | 4,587,000Source | 8,666,000Source | 5,739,000Source | 2,956,000Source | 4,152,000Source |
| Property, Plant and Equipment, NetUSD | 1,000Source | 5,000Source | 2,000Source | 2,000Source | 6,000Source | 2,000Source | 3,000Source | 7,000Source | 3,000Source | 4,000Source | 8,000Source | — |
| Current assets: | ||||||||||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 4,055,000Source | 4,746,000Source | 10,947,000Source | 5,122,000Source | 6,353,000Source | 11,048,000Source | 3,281,000Source | 4,091,000Source | 8,229,000Source | 5,028,000Source | 1,808,000Source | 3,781,000Source |
| Assets, CurrentUSD | 4,697,000Source | 5,323,000Source | 11,334,000Source | 5,576,000Source | 6,884,000Source | 11,279,000Source | 3,930,000Source | 4,428,000Source | 8,592,000Source | 5,615,000Source | 2,934,000Source | 4,152,000Source |
| Prepaid Expense and Other Assets, CurrentUSD | 642,000Source | 577,000Source | 387,000Source | 454,000Source | 531,000Source | 231,000Source | 649,000Source | 337,000Source | 363,000Source | 587,000Source | 1,126,000Source | 371,000Source |
| Operating Lease, Right-of-Use AssetUSD | 84,000Source | 131,000Source | 44,000Source | 97,000Source | 141,000Source | 58,000Source | 109,000Source | 152,000Source | 71,000Source | 120,000Source | 14,000Source | — |
| Other Assets, NoncurrentUSD | — | — | — | — | — | — | — | — | — | — | — | 0Source |
| LIABILITIES AND EQUITY | ||||||||||||
| LiabilitiesUSD | 2,789,000Source | 1,799,000Source | 1,100,000Source | 2,353,000Source | 2,312,000Source | 794,000Source | 2,837,000Source | 1,789,000Source | 2,658,000Source | 1,707,000Source | 2,697,000Source | 1,810,000Source |
| Stockholders’ equity: | ||||||||||||
| Retained Earnings (Accumulated Deficit)USD | -49,037,000Source | -37,793,000Source | -55,337,000Source | -45,678,000Source | -35,670,000Source | -53,694,000Source | -42,786,000Source | -33,420,000Source | -51,696,000Source | -39,740,000Source | -31,533,000Source | -28,926,000Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | — | — | — | — | — | — | — | — | — | — | — | 0Source |
| Stockholders' Equity Attributable to ParentUSD | 1,993,000Source | 3,660,000Source | 10,280,000Source | 3,323,000Source | 4,719,000Source | 10,545,000Source | 1,205,000Source | 2,798,000Source | 6,008,000Source | 4,032,000Source | 259,000Source | 2,342,000Source |
| Additional Paid in Capital, Common StockUSD | 51,030,000Source | 41,453,000Source | 65,617,000Source | 49,000,000Source | 40,389,000Source | 64,239,000Source | 43,991,000Source | 36,218,000Source | 57,704,000Source | 43,772,000Source | 31,792,000Source | 31,267,000Source |
| Liabilities and EquityUSD | 4,782,000Source | 5,459,000Source | 11,380,000Source | 5,675,000Source | 7,031,000Source | 11,339,000Source | 4,042,000Source | 4,587,000Source | 8,666,000Source | 5,739,000Source | 2,956,000Source | 4,152,000Source |
| Current liabilities: | ||||||||||||
| Liabilities, CurrentUSD | 2,759,000Source | 1,715,000Source | 1,100,000Source | 2,309,000Source | 2,216,000Source | 794,000Source | 2,779,000Source | 1,680,000Source | 2,643,000Source | 1,636,000Source | 2,697,000Source | 1,810,000Source |
| Operating Lease, Liability, CurrentUSD | 54,000Source | 47,000Source | 44,000Source | 52,000Source | 45,000Source | 58,000Source | 50,000Source | 43,000Source | 56,000Source | 48,000Source | 14,000Source | — |
| Accounts Payable, CurrentUSD | 1,317,000Source | 1,137,000Source | 526,000Source | 1,297,000Source | 1,236,000Source | 303,000Source | 1,361,000Source | 637,000Source | 1,837,000Source | 897,000Source | 1,410,000Source | 977,000Source |
| Operating Lease, Liability, NoncurrentUSD | 30,000Source | 84,000Source | 0Source | 44,000Source | 96,000Source | 0Source | 58,000Source | 109,000Source | 15,000Source | 71,000Source | 0Source | — |
| Other Liabilities, NoncurrentUSD | — | — | — | — | — | — | — | — | — | — | — | 0Source |
| Additional Financial Items | ||||||||||||
| Accrued Liabilities, CurrentUSD | 1,388,000Source | 531,000Source | 530,000Source | 960,000Source | 935,000Source | 433,000Source | 1,368,000Source | 999,000Source | 750,000Source | 691,000Source | 1,270,000Source | 711,000Source |
cash flow · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash flows from operating activities: | ||||||||||||
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||||||||||
| Share-based Payment Arrangement, Noncash ExpenseUSD | — | — | — | — | — | — | 31,000Source | 220,000Source | 793,000Source | 148,000Source | 388,000Source | 99,000Source |
| Changes in operating assets and liabilities: | ||||||||||||
| Increase (Decrease) in Accounts PayableUSD | — | — | — | — | — | — | -1,507,000Source | 331,000Source | 663,000Source | -387,000Source | 2,159,000Source | -95,000Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | — | — | — | — | — | — | -3,685,000Source | -1,736,000Source | -10,186,000Source | -8,611,000Source | -8,990,000Source | -7,135,000Source |
| Cash flows from investing activities: | ||||||||||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | — | — | — | — | — | — | — | — | -3,000Source | 0Source | -8,000Source | 3,782,000Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | — | — | — | — | — | — | — | — | 3,000Source | 0Source | 8,000Source | — |
| Cash flows from financing activities: | ||||||||||||
| Net Cash Provided by (Used in) Financing ActivitiesUSD | — | — | — | — | — | — | 6,504,000Source | -11,000Source | 13,390,000Source | 11,831,000Source | 10,797,000Source | 3,432,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | — | — | — | — | — | — | 2,819,000Source | -1,747,000Source | 3,201,000Source | 3,220,000Source | 1,799,000Source | 79,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | — | — | 4,055,000Source | 4,746,000Source | 10,947,000Source | 5,122,000Source | 11,048,000Source | 3,281,000Source | 8,229,000Source | 5,028,000Source | 1,808,000Source | 3,781,000Source |
| Supplemental disclosure of cash flow information: | ||||||||||||
| Interest Paid, Excluding Capitalized Interest, Operating ActivitiesUSD | — | — | — | — | — | — | — | — | — | — | 0Source | 21,000Source |
| Additional Financial Items | ||||||||||||
| Share-based Payment Arrangement, ExpenseUSD | — | — | 465,000Source | 37,000Source | 34,000Source | 41,000Source | 31,000Source | 220,000Source | 793,000Source | 148,000Source | 388,000Source | 99,000Source |
| Amortization of Debt Issuance Costs and DiscountsUSD | — | — | — | — | — | — | — | — | — | 0Source | 2,104,000Source | — |
| DepreciationUSD | — | — | 1,000Source | 1,000Source | 0Source | 1,000Source | 1,000Source | 1,000Source | 4,000Source | 4,000Source | 4,000Source | — |
| Gain (Loss) on Derivative Instruments, Net, PretaxUSD | — | — | — | — | — | — | — | — | — | — | — | 0Source |
| Gain (Loss) on Extinguishment of DebtUSD | — | — | — | — | — | — | — | — | — | — | 0Source | 0Source |
| General and Administrative ExpenseUSD | — | — | 1,596,000Source | 1,005,000Source | 1,241,000Source | 1,018,000Source | 1,642,000Source | 1,411,000Source | 5,158,000Source | 4,467,000Source | 8,155,000Source | 5,758,000Source |
| Income Tax Expense (Benefit)USD | — | — | — | — | — | — | — | — | 3,000Source | — | — | — |
| Net Income (Loss) Attributable to ParentUSD | — | — | -3,359,000Source | -2,123,000Source | -1,643,000Source | -2,892,000Source | -1,998,000Source | -3,046,000Source | -11,956,000Source | -8,207,000Source | -13,037,000Source | -7,024,000Source |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | — | — | — | — | — | — | — | — | -11,956,000Source | -10,118,000Source | — | — |
| Operating ExpensesUSD | — | — | 3,365,000Source | 2,130,000Source | 1,648,000Source | 2,897,000Source | 2,003,000Source | 3,051,000Source | 11,977,000Source | 8,235,000Source | 11,387,000Source | 6,928,000Source |
| Other Nonoperating Income (Expense)USD | — | — | — | 0Source | — | — | — | — | — | 0Source | 250,000Source | 0Source |
| Proceeds from Issuance of Common StockUSD | — | — | — | — | — | — | 6,819,000Source | 0Source | — | — | 12,250,000Source | — |
income statement · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Income (Loss)USD | — | — | -3,365,000Source | -2,130,000Source | -1,648,000Source | -2,897,000Source | -2,003,000Source | -3,051,000Source | -11,977,000Source | -8,235,000Source | -11,387,000Source | -6,928,000Source |
| Other Nonoperating Income (Expense)USD | — | — | — | 0Source | — | — | — | — | — | 0Source | 250,000Source | 0Source |
| Income Tax Expense (Benefit)USD | — | — | — | — | — | — | — | — | 3,000Source | — | — | — |
| Net Income (Loss) Attributable to ParentUSD | — | — | -3,359,000Source | -2,123,000Source | -1,643,000Source | -2,892,000Source | -1,998,000Source | -3,046,000Source | -11,956,000Source | -8,207,000Source | -13,037,000Source | -7,024,000Source |
| Earnings Per Share, BasicUSD per share | — | — | — | — | -0.91Source | -36.72Source | -1.61Source | -162.3Source | -121.8Source | -55.21Source | -28.25Source | -0.69Source |
| Earnings Per Share, DilutedUSD per share | — | — | — | — | -0.91Source | -36.72Source | -1.61Source | -162.3Source | -121.8Source | -55.21Source | -28.25Source | -0.69Source |
| Weighted Average Number of Shares Outstanding, Basicshares | — | — | — | — | 1,804,951Source | 78,757Source | 1,241,001Source | 18,768Source | 98,162Source | 183,278Source | 461,566Source | 10,143,205Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | — | — | — | — | 1,804,951Source | 78,757Source | 1,241,001Source | 18,768Source | 98,162Source | 183,278Source | 461,566Source | 10,143,205Source |
| Additional Financial Items | ||||||||||||
| Gain (Loss) on Derivative Instruments, Net, PretaxUSD | — | — | — | — | — | — | — | — | — | — | — | 0Source |
| General and Administrative ExpenseUSD | — | — | 1,596,000Source | 1,005,000Source | 1,241,000Source | 1,018,000Source | 1,642,000Source | 1,411,000Source | 5,158,000Source | 4,467,000Source | 8,155,000Source | 5,758,000Source |
| Interest Income (Expense), Nonoperating, NetUSD | — | — | 6,000Source | 7,000Source | 5,000Source | 5,000Source | 5,000Source | 5,000Source | 21,000Source | 25,000Source | -2,082,000Source | 26,000Source |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | — | — | — | — | — | — | — | — | -11,956,000Source | -10,118,000Source | — | — |
| Operating ExpensesUSD | — | — | 3,365,000Source | 2,130,000Source | 1,648,000Source | 2,897,000Source | 2,003,000Source | 3,051,000Source | 11,977,000Source | 8,235,000Source | 11,387,000Source | 6,928,000Source |
| Research and Development ExpenseUSD | — | — | 1,769,000Source | 1,125,000Source | 407,000Source | 1,879,000Source | 361,000Source | 1,640,000Source | 6,819,000Source | 3,768,000Source | 3,232,000Source | 1,170,000Source |
Offerings
Registration 333-293065
Filing attachments
ex992_ersrelease.htm · 8-K · 2026-09-08
EX-99.2 3 ex992_ersrelease.htm EX-99.2 Document Exhibit 99.2 GRI Bio Presents New Phase 2a Data at ERS 2026 Defining GRI-0621's Mechanism of Action in IPF Across Nine Mechanistic Pillars New whole blood RNA sequencing data identified coordinated, consistent change in genes governing immune re-balancing, myofibroblast inhibition, fibrolysis, basement membrane repair, re-epithelialization, antitussive effect and GI protection Signals observed from at least two independent measurement modal…
Read attachment ↗ex991_pressreleaseodd.htm · 8-K · 2026-06-18
EX-99.1 2 ex991_pressreleaseodd.htm EX-99.1 Document Exhibit 99.1 GRI Bio Secures FDA Orphan Drug Designation for GRI-0621 (Tazarotene) in Idiopathic Pulmonary Fibrosis Designation highlights significant regulatory milestone and provides a potential pathway to seven years of U.S. market exclusivity LA JOLLA, CA, June 18, 2026 -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology company developing innovative therapies for inflammatory, fibrotic and autoimmune disea…
Read attachment ↗ex991_pressreleaseq126earn.htm · 8-K · 2026-05-14
EX-99.1 2 ex991_pressreleaseq126earn.htm EX-99.1 Document Exhibit 99.1 GRI Bio Reports First Quarter 2026 Financial Results, New Data Reinforcing Differentiated Profile of GRI-0621 in Idiopathic Pulmonary Fibrosis and Highlights Continued Advancement of Differentiated Immune-Modulating Pipeline Phase 2a data show zero cough and 60% lower treatment-related diarrhea than placebo despite higher nintedanib use in the active arm - suggesting GRI-0621 may mitigate nintedanib-related GI-toxiciti…
Read attachment ↗ex991_pressreleaseye25earn.htm · 8-K · 2026-02-04
Exhibit 99.1 GRI Bio Reiterates Full Year 2025 Financial Results, Strengthens Balance Sheet and Summarizes Key Recent Highlights Company reported $8.2 million in cash and cash equivalents at December 31, 2025 and raised additional $6.5 million in gross proceeds in January 2026 Balance sheet strengthened to fund operations into Q1 2027 Strong Phase 2a clinical data for GRI-0621 in idiopathic pulmonary fibrosis reinforce clinical proof-of-concept and therapeutic differentiation GRI-0803 focus…
Read attachment ↗ex991_pressreleaseaddition.htm · 8-K · 2026-01-28
Exhibit 99.1 GRI Bio Delivers Compelling New Phase 2a Gene Expression Data Demonstrating Improvements in Key Drivers of Fibrosis and Lung Repair in IPF Multiple Independent Molecular Signals Converge to Validate GRI-0621 as a Potential Disease-Modifying Therapy LA JOLLA, CA, January 28, 2026 -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology company advancing an innovative pipeline of immune cell modulators for the treatment of inflammatory, fibrotic and autoimmune d…
Read attachment ↗ex991_pressreleasereverses.htm · 8-K · 2026-01-21
Exhibit 99.1 GRI Bio Announces Reverse Stock Split GRI’s common stock is expected to begin trading on a post-split adjusted basis on January 26, 2026 LA JOLLA, CA, January 21, 2026 - GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology company advancing an innovative pipeline of immune cell modulators for the treatment of inflammatory, fibrotic and autoimmune diseases, today announced that the board of directors of the Company approved a 1-for-28 reverse stock split (the …
Read attachment ↗